Duran Tok1, Fuat Ekiz2, Omer Basar3, Sahin Coban4, Gulfer Ozturk5. 1. Turkish Armed Forces Health Command Ankara, Turkey. 2. Department of Gastroenterology, Hatay Antakya State Hospital Turkey. 3. Department of Gastroenterology, Hacettepe University School of Medicine Ankara, Turkey. 4. Department of Gastroenterology, Dışkapı Education and Research Hospital Ankara, Turkey. 5. Department of Biochemistry, Dışkapı Education and Research Hospital Ankara, Turkey.
Abstract
BACKGROUND AND AIM: Early detection of fibrosis should be the main goal of treatment in liver cirrhosis. Endocan, previously called endothelial cell specific molecule-1, is expressed by endothelial cells, primarily in the lung, liver and kidney. In this study, we aimed to examine the correlation of liver fibrosis stage, histological activity and grade of steatosis between serum levels of endocan in patients with chronic hepatitis B (CHB), chronic hepatitis C (CHC) and non-alcoholic fatty liver disease (NAFLD). PATIENTS AND METHODS: This cross-sectional study includes a total of 146 subjects. 55 CHB patients, 19 CHC patients, 38 NAFLD patients and 34 healthy controls were enrolled consecutively. Liver biopsies were performed in all patients with chronic viral hepatitis. NAFLD patients had either grade 2 or grade 3 steatosis on ultrasonography and elevated liver enzymes above the upper normal limits. Serum endocan levels were assessed from blood samples obtained at admission. RESULTS: Gender distribution was similar among the groups (p=0.056). The mean age of the CHB patients was 45.8±12.1, CHC patients was 55.0±12.8 years, NAFLD patients was 42.8±10.8, while control group was 39.4±13.6 years old. Patients with CHC were older than all the others (p=0.001). Serum endocan levels were statistically significantly lower in CHB, CHC and NAFLD groups when compared with controls. Although levels of endocan were lower in CHB and CHC groups when compared with NAFLD group, the difference was not statistically significant. CONCLUSION: Serum endocan concentrations decrease in patients with liver disease. Unlike previous studies, we showed a negative correlation between endocan levels and inflammation stage of chronic hepatitis. However, further studies are needed to establish the association between endocan levels, liver fibrosis and hepatic inflammation.
BACKGROUND AND AIM: Early detection of fibrosis should be the main goal of treatment in liver cirrhosis. Endocan, previously called endothelial cell specific molecule-1, is expressed by endothelial cells, primarily in the lung, liver and kidney. In this study, we aimed to examine the correlation of liver fibrosis stage, histological activity and grade of steatosis between serum levels of endocan in patients with chronic hepatitis B (CHB), chronic hepatitis C (CHC) and non-alcoholic fatty liver disease (NAFLD). PATIENTS AND METHODS: This cross-sectional study includes a total of 146 subjects. 55 CHB patients, 19 CHCpatients, 38 NAFLD patients and 34 healthy controls were enrolled consecutively. Liver biopsies were performed in all patients with chronic viral hepatitis. NAFLD patients had either grade 2 or grade 3 steatosis on ultrasonography and elevated liver enzymes above the upper normal limits. Serum endocan levels were assessed from blood samples obtained at admission. RESULTS: Gender distribution was similar among the groups (p=0.056). The mean age of the CHB patients was 45.8±12.1, CHCpatients was 55.0±12.8 years, NAFLD patients was 42.8±10.8, while control group was 39.4±13.6 years old. Patients with CHC were older than all the others (p=0.001). Serum endocan levels were statistically significantly lower in CHB, CHC and NAFLD groups when compared with controls. Although levels of endocan were lower in CHB and CHC groups when compared with NAFLD group, the difference was not statistically significant. CONCLUSION: Serum endocan concentrations decrease in patients with liver disease. Unlike previous studies, we showed a negative correlation between endocan levels and inflammation stage of chronic hepatitis. However, further studies are needed to establish the association between endocan levels, liver fibrosis and hepatic inflammation.
Authors: I Balta; S Balta; S Demirkol; D P Mikhailidis; T Celik; M Akhan; O Kurt; Y G Kurt; I Aydin; S Kilic Journal: Br J Dermatol Date: 2013-11 Impact factor: 9.302
Authors: Aleksandra Klisić; Nebojša Kavarić; Ludovico Abenavoli; Verica Stanišić; Vesna Spasojević-Kalimanovska; Jelena Kotur-Stevuljević; Ana Ninić Journal: J Med Biochem Date: 2020-09-02 Impact factor: 3.402
Authors: Carlos Alonso Domínguez-Alemán; Luis Alberto Sánchez-Vargas; Karina Guadalupe Hernández-Flores; Andrea Isabel Torres-Zugaide; Arturo Reyes-Sandoval; Leticia Cedillo-Barrón; Ricardo Remes-Ruiz; Héctor Vivanco-Cid Journal: Microorganisms Date: 2021-06-15